ARG2 and chronic myelogenous leukemia, BCR-ABL1 positive: Given its potential role in driving tumorigenesis, and the significantly greater induction in CML cells (at least 5-fold higher) [15], ARG2 might therefore represent a druggable target and therapeutic window in hypoxic CML progenitors compared to normal progenitors.